Starling Oncology (STLNW) Interest & Investment Income (2020 - 2023)

Starling Oncology (STLNW) has reported Interest & Investment Income for 3 consecutive years, with $940000.0 the latest figure, recorded in Q3 2023.

• For the quarter ending Q3 2023, Interest & Investment Income changed N/A year-over-year to $940000.0; the trailing twelve-month figure through Sep 2023 stood at $3.2 million (up 54763.75% YoY), and the FY2020 full-year result was $254149.0, changed N/A from the prior year.
• Interest & Investment Income declined to $940000.0 in Q3 2023 per STLNW's latest filing, from $1.0 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $1.2 million in Q1 2023 and bottomed at $5798.0 in Q3 2021.
• Historically, Interest & Investment Income has averaged $383437.7 across 3 years, with a median of $73393.0 in 2020.
• The widest YoY moves for Interest & Investment Income: up 91.48% in 2021, down 92.1% in 2021.
• Over 3 years, Interest & Investment Income stood at $59248.0 in 2020, then slumped by 90.21% to $5798.0 in 2021, then surged by 16112.49% to $940000.0 in 2023.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $940000.0, $1.0 million, and $1.2 million for Q3 2023, Q2 2023, and Q1 2023 respectively.